IMMUNE-MEDIATED NECROTIZING MYOPATHY
Clinical trials for IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early IVIg boost may tame muscle disease before it disables
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to better improvement than steroids alone. Myositis causes muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past year with ce…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 17, 2026 06:06 UTC
-
New hope for myositis patients: long-term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases known as idiopathic inflammatory myopathy (IIM). Only people who completed an earlier study of this drug can join. Participants will receive the drug for up to 51 mon…
Matched conditions: IMMUNE-MEDIATED NECROTIZING MYOPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 06:03 UTC